AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05964114
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial dosing based on (a combinations of) pharmacokinetic models tailored to the individual patient. Dose adjustment starting dose (within registered dosing range).
Trial: NCT05236972
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200mg iv drip Q3W
Trial: NCT05236972
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
Trial: NCT06233877
Drug: G-GLIP plus Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin plus Mitomycin C
Trial: NCT01476163
Drug: migalastat HCl
RxNorm normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150 mg capsule taken every other day by mouth. An inactive reminder capsule may be provided to take on the days in between migalastat HCl
Trial: NCT05675748
Drug: Azvudine
RxNorm normalized name: Azvudine
DrugBank: Azvudine (DB16407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azvudine tablets are taken orally 5mg daily for a maximum of 14 days
Trial: NCT01822951
Drug: Cerebrolysin
RxNorm normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.~Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o.
Trial: NCT01822951
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.
Trial: NCT06401343
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants randomized to the study group will received Empagliflozin 10mg q.d. for 12 months.
Trial: NCT05156645
Drug: SCTA01 and SCTA01C
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diluted by 0.9% normal saline
Trial: NCT05502991
Drug: Tislelizumab plus Bevacizumab
RxNorm normalized name: Tislelizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks
Trial: NCT05949541
Drug: Everolimus 10 mg
RxNorm normalized name: everolimus 10 MG
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus is a kind of mTOR inhibitor which has been approved to use in several kinds of cancers, especially in metastatic breast cancer.
Trial: NCT05949541
Drug: CDK4/6 Inhibitor SHR6390
RxNorm normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
Trial: NCT05949541
Drug: Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
Trial: NCT05771402
Drug: Anti-PD-1 antibody
RxNorm normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
Trial: NCT05771402
Drug: Peg-IFNα
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once/week, 180μg/time, subcutaneous injection
Trial: NCT04865939
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravesical gemcitabine instilled into bladder during surgery (drained prior to entry into bladder).
Trial: NCT06730308
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly albumin-bound paclitaxel (50 mg/m²) and cisplatin (25 mg/m²)
Trial: NCT06730308
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 2mg/kg, qd, concurrent with radiotherapy
Trial: NCT05629806
Drug: Metformin plus pioglitazone
RxNorm normalized name: metformin / pioglitazone
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After the screening period, eligible subjects were admitted to two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. Then the subjects were titrated onto the alternative treatment of 50mg acarbose three times daily for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
Trial: NCT05629806
Drug: Acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the screening period, eligible subjects were admitted to 50mg acarbose three times daily for 12 weeks. Then the subjects were titrated onto the alternative treatment of two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
Trial: NCT06303128
Drug: Amoxicillin 250 MG
RxNorm normalized name: amoxicillin 250 MG
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid amoxicillin 250mg PO
Trial: NCT06303128
Drug: Amoxicillin 62.5mg
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given first in two-dose group, liquid amoxicillin 62.5mg PO
Trial: NCT06303128
Drug: Amoxicillin 187.5mg
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given second in two-dose group, liquid amoxicillin 187.5mg PO
Trial: NCT06731153
Drug: Ivarmacitinib
RxNorm normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a selective Janus kinase 1 inhibitor
Trial: NCT06731153
Drug: Camrelizumab (SHR-1210)
RxNorm normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: a humanised anti-programmed death-1 (anti PD-1) antibody
Trial: NCT06731153
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage.
Trial: NCT04800614
Drug: sitravatinib
RxNorm normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sitravatinib on Day 1 of each of 3 periods
Trial: NCT05007145
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 Inhibitor 200mg D1 Q3W
Trial: NCT05007145
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 125 mg/m\^2 D1/D8 Q3W
Trial: NCT05007145
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2 D1 Q3W
Trial: NCT04189133
Drug: Lutropin alfa
RxNorm normalized name: Lutropin alfa
DrugBank: Lutropin alfa (DB00044)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily increasing dosages of lutropin alfa
Trial: NCT04189133
Drug: Human chorionic gonadotropin
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human chorionic gonadotropin increasing administration
Trial: NCT05595408
Drug: adjuvant immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immunotherapy for one year
Trial: NCT05313750
Drug: anti-infective therapy sitafloxacin
RxNorm normalized name: gentian violet
DrugBank: Sitafloxacin (DB13261)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: anti-infective therapy
Trial: NCT05313750
Drug: anti-infective therapy levofloxacin
RxNorm normalized name: gentian violet
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anti-infective therapy
Trial: NCT04865211
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of liposomal bupivicaine as intraoperative local anesthesia
Trial: NCT04742309
Drug: Pecs-2 block (single injection)
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For Pecs-2 blocks, the needle will be advanced to the tissue plane between the pectoralis major and minor muscles at the vicinity of the pectoral branch of the acromiothoracic artery where 10 mL of local anesthetic will be deposited. In a similar manner, 20 mL will be deposited at the level of the third rib above the serratus anterior muscle with the intent of spreading injectate to the axilla. The study fluid will be ropivacaine 0.3% with epinephrine.
Trial: NCT04742309
Drug: Paravertebral block (single injection)
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For paravertebral blocks, ropivacaine 0.5% (with epinephrine) 9 mL will be administered at each of two levels per side: the T3 and T5 levels for sides without axillary involvement; and at the T2 and T4 level for sides with axillary involvement.
Trial: NCT05320068
Drug: Oral Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A blinded capsule that contains 125mg of vancomycin every 6 hours during 10 days.
Trial: NCT04865211
Drug: Bupivacaine Injection
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of bupivicaine as intraoperative local anesthesia
Trial: NCT06125340
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose amoxicillin (approved by Health Canada) to be given x 5 days.
Trial: NCT05693545
Drug: phenoxymethyl penicillin
RxNorm normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylaxis
Trial: NCT06304740
Drug: IMG-007
RxNorm normalized name: IMG-7289
DrugBank: IMG-7289 (DB15126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of IMG-007
Trial: NCT05649345
Drug: TR64
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TR64 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
Trial: NCT05737433
Drug: [14C]-rencofilstat 225mg
DrugBank: Rencofilstat (DB18246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radio-labelled 225mg oral dose of rencofilstat
Trial: NCT06731595
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: colchicine 0.6mg oral twice daily for 7 days
Trial: NCT04775550
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
Trial: NCT04775550
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
Trial: NCT04775550
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral, dosage per protocol, days 1-21 per cycle
Trial: NCT04775550
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral, dosage per protocol, dose days vary per cycle. Cycle =28 days
Trial: NCT02865109
Drug: Nusinersen
RxNorm normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intrathecal injection
Trial: NCT05507372
Drug: Pimozide 1 MG
RxNorm normalized name: pimozide 1 MG
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine Receptor Antagonist - Oral Pimozide
Trial: NCT05020704
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SGLT2inhibitor
Trial: NCT04247906
Drug: Narsoplimab
RxNorm normalized name: Narsoplimab
DrugBank: Narsoplimab (DB16418)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05341323
Drug: Ketamine.
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peritonsillar infiltration of ketamine
Trial: NCT04944836
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the study group, these will contain 50 mg of clomiphene citrate. In the control group, these will be placebo. These will be taken every other day for seven months beginning four weeks prior to surgery and extending for six months after surgery. After enrollment patients will be randomized. Patient will be assigned to the 2 groups using a permuted block randomization scheme with blocks of size 2, 4, and 6. Prior to initiation of the study opaque sealed envelopes will be prepared and thoroughly shuffled and then used sequentially during the study. These randomization assignments will be available to the pharmacy in a web-based format or by cards in sealed envelopes. A nonparticipant in the study (the pharmacy at our institution) will administer this process.
Trial: NCT05571176
Drug: S-ketamine
RxNorm normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: S-ketamine infusion 0.29 mg/kg/h for 4 hours
Trial: NCT04885894
Drug: Zeposia
RxNorm normalized name: Zeposia
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants with MS will be divided into two treatment groups: those who will begin to take Zeposia, and those who plan to be begin treatment with high dose oral efficacy medication. The HC group will be free of neurological disease or injury and will be matched to the MS groups for age, gender, and education.
Trial: NCT05341323
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peritonsillar infiltration of Bupivacaine
Trial: NCT06034379
Drug: 0.01% atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.
Trial: NCT05071716
Drug: Rifaximin SSD
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
Trial: NCT05834036
Drug: Amoxicillin Oral Capsule
RxNorm normalized name: amoxicillin Oral Capsule
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 875mg every 12 hours for 7 days.
Trial: NCT05313477
Drug: Ergocalciferol Capsules
RxNorm normalized name: Ergocalciferol Capsules
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Depend on initial 25(OH) vitamin D level If \<10ng/mL, 60000U of Ergocalciferol capsules per week If 10-19.9ng/mL, 40000U of Ergocalciferol capsules per week If \>20 ng/mL, 20000U of Ergocalciferol capsule per week
Trial: NCT05313477
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000mg of Calcium carbonate daily
Trial: NCT04204928
Drug: pralsetinib (BLU-667)
RxNorm normalized name: pralsetinib
DrugBank: Pralsetinib (DB15822)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pralsetinib will be administered orally (PO) at a dose of 400 mg once daily (QD) in continuous 28 day cycles
Trial: NCT06189404
Drug: Tigulixostat
RxNorm normalized name: Tigulixostat
DrugBank: Tigulixostat (DB18799)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral dose
Trial: NCT05134662
Drug: ALT-801
RxNorm normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected subcutaneously (SC)
Trial: NCT05335109
Drug: Xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xenon is injected into the body by inhalation in the form of xenon-oxygen mixtures, in which the concentration of xenon is 30%, and oxygen is 30%.~Xenon inhalation is carried out for 30 min daily for 3 days.
Trial: NCT06511076
Drug: Zilucoplan
RxNorm normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single sc injection of zilucoplan in the pre-specified sequence.
Trial: NCT05335109
Drug: Oxygen 30 %
RxNorm normalized name: oxygen 30 %
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxygen-air mixture is injected into the body by inhalation. The oxygen concentration is 30%.~Inhalation of oxygen-air mixture is carried out for 30 min daily for 3 days
Trial: NCT06293300
Drug: BoNT A
RxNorm normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with TBI-associated photophobia will come one time in person to the clinic and receive 35 Units of BoNT-A injected in 7 forehead sites (0.1 cc in each location).
Trial: NCT00488605
Drug: Prednisone, Vinblastin, 6-mercaptopuroine
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial Therapy:Prednisone- by mouth 3 times/day daily as a 4-week course, then gradually decreased over 2 more weeks. Vinblastine-IV (into a vein)1 day/week for 6 weeks. Patients w/o evidence of active disease at this time will proceed to continuation therapy. If disease is improved or unchanged, pts. will receive additional therapy with: Prednisone- 3 divided doses by mouth for 3 days every week, from week 7-12. Vinblastine- IV 1day/week for 6 more weeks. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP:by mouth daily until the end of month 12. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12.
Trial: NCT04469959
Drug: L-Dopa
RxNorm normalized name: L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Generic 25/100mg carbidopa/levodopa (Sinemet)capsules will be administered in this study. Participants will begin randomized double blinded 3- week trial of Levodopa. Dose titration starting at 150 mg /daily to maximum of 450 mg daily three times a day for three weeks.~After one week of taper participants will enter step 2 phase of study where carbidopa/levodopa matched placebo will be administered for 3 weeks afterwards dose will be slowly tapered over next 7 days.
Trial: NCT04738136
Drug: S-1226
RxNorm normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in vapour form within a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8%, or 12% CO2
Trial: NCT06162611
Drug: Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single pill of oral levonorgestrel 1.5mg X 1 dose (e.g. Plan B) same day as contraceptive implant insertion
Trial: NCT06619665
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil tablet taken once orally
Trial: NCT06619665
Drug: Modafinil placebo
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil placebo tablet taken once orally
Trial: NCT05745207
Drug: E2086
RxNorm normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E2086 tablets.